ILA secures US grant for ISLA-101 clinical development support

Island Pharmaceuticals Ltd (ASX: ILA) has announced the acquisition of a new grant to support the planned Phase 2a human clinical trial (PEACH study) of ISLA-101 in treating dengue fever. This grant is part of their collaborative partnership with Island Pharmaceuticals to advance the development of ISLA-101, a well-known drug candidate being repurposed for preventing and treating dengue and other mosquito-borne diseases.

The substantial amount of US$1.3 million will specifically support laboratory testing and data analysis throughout the anticipated clinical trial conducted at SUNY. The studies conducted as part of the trial are expected to contribute to a better understanding of dengue infections, potentially leading to the identification of biomarkers and the development of effective therapies and diagnostics.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com